Exploiting Cancer Metabolism and Drug Efflux with Bystander-Assisted Immunotherapy

通过旁观者辅助免疫疗法利用癌症代谢和药物流出

• 批准号: 10655088
• 负责人: Rock Mancini
• 金额: $ 31.95万
• 依托单位: MIAMI UNIVERSITY OXFORD
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-07-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10655088
• 关键词: ABCB1 gene; ATP-binding cassette transport; Active Biological Transport; Address; Agreement; Allografting; Antineoplastic Agents; Area; Binding; Biodistribution; Biological Models; Cancer Patient; Cancer cell line; Carrier Proteins; Cell Survival; Cells; Coculture Techniques; Cohort Studies; Coupling; Data; Development; Diffusion; Disseminated Malignant Neoplasm; Drug Efflux; Drug Transport; Drug resistance; Enzyme Tests; Enzymes; Exhibits; Extracellular Space; Goals; Immune; Immune response; Immune system; Immunocompetent; Immunomodulators; Immunotherapeutic agent; Immunotherapy; In Vitro; Malignant Neoplasms; Malignant neoplasm of prostate; Mediating; Metabolic; Metabolic Pathway; Metabolism; Methods; Modality; Multi-Drug Resistance; Mus; Outcome; Pharmaceutical Preparations; Phenotype; Predisposition; Process; Prodrugs; Progression-Free Survivals; RNA Interference; Reporting; Research; Resistance development; Specificity; Techniques; Testing; Therapeutic; Toxic effect; Tumor Volume; Vision; Work; acquired drug resistance; anti-cancer; anti-cancer therapeutic; base; cancer cell; cancer drug resistance; cancer immunotherapy; cancer therapy; cancer type; chemotherapy; conventional therapy; cytotoxic; drug metabolism; immunogenicity; in vivo; in vivo Model; inhibitor; mortality; mouse model; multidrug resistant cancer; nanomedicine; novel drug class; novel therapeutics; overexpression; programs; prostate cancer model; rational design; refractory cancer; side effect; small molecule; synthetic enzyme; tumor metabolism; tumor microenvironment; tumorigenesis

ABSTRACT. Two hallmarks of drug resistance in cancers are irregular metabolism and drug efflux. In multidrug- resistant cancers, both of these processes disarm the efficacy of chemotherapeutics, ultimately resulting in de- creased chemotherapeutic efficacy and increased mortality. Several strategies in development attempt to miti- gate the effects of drug resistance by modulating specific metabolic pathways or disrupting drug efflux. Specifi- cally, these strategies include inhibitors, interference RNAs, and nanomedicine approaches. However, a funda- mental challenge to these strategies is the off-target toxicity that arises from disrupting metabolism or drug efflux mediated by P-glycoprotein (P-gp), as these mechanisms are also critical to a number of healthy processes throughout the body. To address this, our long-term objective is to develop a therapeutic strategy that exploits both of these mechanisms of drug resistance in tandem to generate a therapeutic anti-cancer immune repsonse. Our central hypothesis is that rationally designed prodrugs can co-opt cancer cell metabolism and drug efflux to cause an anti-cancer immune response via a mechanism of action we have termed Bystander Assisted Immu- noTherapy (BAIT). In BAIT, an enzyme-directed prodrug is first metabolized to an immunotherapeutic metabolite by the irregular metabolism of multidrug-resistant cancer cells. Next, the immunotherapeutic is transported, via P-gp-mediated drug efflux, to the extracellular space. This results in the activation of bystander immune cells in local proximity, which initiate an anti-cancer immune response. Because BAIT requires tandem metabolism and drug efflux, we anticipate a uniquely enhanced specificity for multidrug-resistant phenotypes that exhibit both of these processes. To develop rationally designed BAIT prodrugs, we first identify small-molecule immunothera- peutics that are susceptible to drug efflux. In concurrent studies, we also develop synthetic enzyme-directing groups that modulate the activity of immunotherapeutics and are specifically removed by enzymes expressed in the irregular metabolism of multidrug-resistant cancer cells. Combining these two research areas, we generate enzyme-directed BAIT prodrugs that confer immunogenicity to multidrug-resistant cancers. In-vitro, this is con- firmed in co-cultures of immune cells and cancer cell lines that express these metabolic enzymes and P-gp. In- vivo, we use a murine model system for prostate cancer (TRAMP-C2 allograft) to demonstrate that BAIT pro- drugs result in lowered toxicity, decreased tumor volume, and increased progression-free survival, relative to conventional immunotherapeutics in immunocompetent mice. Taken together, we envision that this research will establish BAIT as a therapeutic strategy that is enhanced, rather than disarmed, by drug resistance. It is our long-term vision that this strategy could be widely applicable to multidrug-resistant cancers that evade the action of conventional therapies through altered metabolisms and drug efflux.

抽象的。癌症中耐药性的两个标志是不规则的代谢和药物外排。在多药中 抗性癌症，这两个过程都解除了化学治疗疗法的功效，最终导致了 化学治疗功效和死亡率增加。开发中的几种策略试图弥补 门通过调节特定的代谢途径或破坏药物外排的耐药性影响。指定 这些策略包括抑制剂，干扰RNA和纳米医学方法。但是， 这些策略的心理挑战是破坏新陈代谢或药物外的脱靶毒性 由P-糖蛋白（P-GP）介导，因为这些机制对于许多健康过程也至关重要 整个身体。为了解决这个问题，我们的长期目标是制定一种利用的治疗策略 这两种在串联中产生治疗性抗癌免疫复制的机制。 我们的中心假设是，理性设计的前药可以选择癌细胞代谢和药物排出 通过一种作用机制引起抗癌免疫反应，我们称其为旁观者协助启发 Notherapy（诱饵）。在诱饵中，酶指导的前药首先被代谢为免疫治疗代谢物 通过多药耐药细胞的不规则代谢。接下来，通过 P-gp介导的药物外排向细胞外空间。这导致旁观者免疫细胞激活 局部接近，启动抗癌免疫反应。因为诱饵需要串联代谢和 药物外，我们预计对抗多药的表型的特异性具有独特的特异性 这些过程。为了开发合理设计的诱饵前药，我们首先确定了小分子免疫。 容易受到药物外排的影响。在并发研究中，我们还开发了合成酶指导 调节免疫疗法活性并通过在 多药耐药性癌细胞的不规则代谢。结合了这两个研究领域，我们产生 酶指导的诱饵前药将免疫原性赋予多药耐药性癌症。无效，这是 固定在表达这些代谢酶和P-gp的免疫细胞和癌细胞系的共培养中。在- Vivo，我们使用前列腺癌（Tramp-C2同种异体移植物）的鼠模型系统来证明诱饵促进 药物相对于 免疫能力小鼠中的常规免疫治疗药。综上所述，我们设想这项研究将 将诱饵作为一种治疗策略，通过耐药性增强而不是解除武装。这是我们的 长期的愿景，即该策略可以广泛适用于逃避行动的多药耐药性癌症 传统疗法通过改变的代谢和药物外排。